During subgroup analysis , a more beneficial effect of magnesium supplementation was observed in diabetic subjects with hypomagnesaemia .
CONCLUSIONS Magnesium supplementation can produce a favourable effect on FPG , HDL , LDL , TG and SBP .
BACKGROUND Cardiovascular disorders remain the leading cause of death in type 2 diabetic patients .
In the present study , a systematic review and a meta- analysis of r and omised controlled trials ( RCTs ) were conducted aim ing to evaluate the effect of magnesium supplementation on  type 2 diabetes ( T2D ) associated cardiovascular risk factors in both diabetic and nondiabetic individuals .
Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial.
BACKGROUND Given that role of magnesium in insulin secretion is uncertain , our objective was to determine whether oral supplementation with magnesium chloride ( MgCl(2 ) ) improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia . MATERIAL S AND METHODS Eligible individuals were non-diabetic , normo-tensive men and non-diabetic , normo-tensive , non-pregnant women with serum magnesium levels ≤0·70 mM/L ; they were enrolled in a r and omized double-blind clinical trial to receive either 50 mL of 5 % MgCl(2 ) solution or 50 mL of inactive solution daily for 3 months . The primary trial end point was a change in the AUC of the hyperbolic model of beta-cell function ( HMbCF ) derived from the fasting state . Individuals , caregivers and personnel who assessed the outcomes were all blinded to the group assignments . RESULTS A total of 54 and 52 individuals were assigned to the MgCl(2 ) and placebo groups , respectively ; five individuals in the MgCl(2 ) group and four in the placebo group dropped out . There were no serious adverse events or side effects because of MgCl(2 ) or placebo . At the beginning of the study , the AUC of the HMbCF was similar in both groups ( AUC = 7·591 and 7·895 cm(2 ) ) ; at the end of follow-up , the curve of the MgCl(2 ) group showed a hyperbolic distribution ( AUC = 18·855 cm(2 ) ) , whereas in the placebo group , there were no changes ( AUC = 7·631 cm(2 ) ) . CONCLUSIONS MgCl(2 ) 2·5 g daily improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia
During subgroup analysis , a more beneficial effect of magnesium supplementation was observed in diabetic subjects with hypomagnesaemia .
CONCLUSIONS Magnesium supplementation can produce a favourable effect on FPG , HDL , LDL , TG and SBP .
BACKGROUND Cardiovascular disorders remain the leading cause of death in type 2 diabetic patients .
In the present study , a systematic review and a meta- analysis of r and omised controlled trials ( RCTs ) were conducted aim ing to evaluate the effect of magnesium supplementation on  type 2 diabetes ( T2D ) associated cardiovascular risk factors in both diabetic and nondiabetic individuals .